Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the ...
Eli Lilly has announced a $3 billion expansion in Kenosha County to its manufacturing facility acquired earlier this year in ...